News Releases

Renowned Biopharma Leaders Join Newly Established Kallyope Clinical Development Advisory Board

August 5th, 2022

Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives

July 21st, 2022

Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Advances Discovery and Development Teams With New Appointments

July 6th, 2022

Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery

May 17th, 2022

Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Adds New Chief Business Officer

April 25th, 2022

Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Strengthens Senior Leadership Team with Key Appointments

March 16th, 2022

Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs

February 15th, 2022

Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth

August 5th, 2021

Kallyope Inc. Appoints Patrick Flanigan as Chief Financial Officer

June 1st, 2021

Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis

March 25th, 2020

Kallyope Inc. Appoints Peter Hecht to Board of Directors

February 20th, 2020

Kallyope Inc. Appoints Juha Lauren as Chief Business Officer

September 4th, 2019

Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer

February 5th, 2019

Kallyope Inc. Announces $21 Million Expansion of Series B Financing

December 5th, 2018

Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes

June 19th, 2018

Kallyope Inc. Announces $66M Series B Financing to Advance Programs Targeting the Gut-Brain Axis

February 22nd, 2018

Kallyope Inc. Appoints Ann E. Weber and William J. Rieflin to Key Roles

October 27th, 2016

Kallyope Inc. Launches with $44M Series A Financing to Harness the Potential of the Gut-Brain Axis

December 10th, 2015